We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×
Home > Resources > Product News > Content Piece

Linneo Health Awarded EU GMP License

Original story from Linneo Health

Published: Sep 15, 2022   

Complete the form below and we will email you a PDF version of "Linneo Health Awarded EU GMP License"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Analytical Cannabis?

Analytical Cannabis Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Linneo Health Awarded EU GMP License

Linneo Health, a global leader in the research, cultivation, and supply of cannabis to improve human health and wellbeing, has announced that its dried flower facility has been awarded the EU Good Manufacturing Practice (GMP) Part I license by the Spanish Agency of Medicines and Medical Products (Agencia Española de Medicamentos y Productos Sanitarios or AEMPS), for the manufacture of intermediates and finished medicinal cannabis products. This new certification greatly extends Linneo’s existing Part II license for the manufacture of active pharmaceutical ingredients (APIs).

EU-GMP certification is recognized by all medicine regulatory agencies within the EU, as well as the majority of leading agencies over the world.

This certification also brings additional packaging capabilities for Linneo’s dried flower products, allowing Linneo to manufacture in a wide range of formats and sizes, tailored to customer needs. Another benefit is that it avoids the need for the local release of dry flowers, so customers do not have to go through the process of analyzing the product locally. This certification demonstrates Linneo’s unrivalled focus on quality and clinical standards.

Don Bellamy, chief executive officer of Linneo Health, said: “I’m delighted to share the news of our GMP Part I certification, which marks a further milestone for Linneo. Obtaining EU GMP Part I certification of our dried flower facilities perfectly complements our existing Part II license. As our customers and their requirements develop, Linneo is perfectly positioned as the supplier of choice to provide high quality cannabis products, tailored to our customers’ needs.”

Maria José Garcia, quality and RA director of Linneo Health, added: “At Linneo we work continuously to ensure our facilities meet the strictest EU GMP requirements. This certification represents a huge, combined effort of the Linneo team. We are excited to be able to provide our customers with an expanded product offering – our excellent cannabis dried flower, APIs and now finished dosage forms.”


This article has been republished from materials provided by Linneo Health. Note: material may have been edited for length and content. For further information, please contact the cited source.

 

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter

 
Advertisement